doxorubicin hydrochloride

P1/2, N=10, Active, not recruiting, InSightec | Recruiting --> Active, not recruiting | Trial completion date: Jul 2026 --> Oct 2026 | Trial primary completion date: Jan 2026 --> Jun 2026

P2, N=46, Active, not recruiting, Virginia Commonwealth University | Trial completion date: Mar 2026 --> Mar 2027

P2, N=80, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting

Intratumoral redox homeostasis is often implicated in the development of multidrug resistance (MDR), which compromises the oxidative cytotoxicity of anthracycline chemotherapeutics such as doxorubicin (DOX)...As a result of this engineered therapeutic approach, the combination therapy reduced the IC50 of DOX by 87.7-fold compared to free DOX. In summary, this multimodal nanozyme provides a novel strategy to target redox homeostasis and overcome MDR in cancer therapy.

Piceid exhibited dose-dependent cytotoxicity against HeLa cervical cancer cells, inducing marked morphological alterations, although with a higher IC₅₀ than doxorubicin. These findings suggest that piceid may serve as a promising candidate for multi-target immune-modulatory activity to prevent the progress of Cervical Cancer.

Chemotherapy was the principal treatment (62.12%), with cyclophosphamide (69.62%), doxorubicin (53.80%), and paclitaxel (56.33%) as the most prescribed agents. Significant associations were also observed under the recessive model (AA vs. GG + AG: OR = 1.96, 95% CI = 1.0-3.86, p = 0.051) and the allelic model (A vs G: OR = 1.59, 95% CI = 1.06-2.39, p = 0.026). The miR-218-2 rs11134527 A allele confers an increased risk of breast cancer in Bangladeshi women, supporting its potential role as a population-specific genetic biomarker for susceptibility assessment.

We have identified a small molecule produced by a marine sponge as being able to inhibit PTCH1 efflux activity and increase the efficacy of vemurafenib treatment on BRAF-mutated melanoma cells in vitro and in vivo in mice. We found that inhibiting PTCH1 drug efflux activity significantly increased the cytotoxic effect of chemotherapies such as doxorubicin and docetaxel in three TNBC cell lines. Overall, our findings suggest that PTCH1 plays a role in the resistance of TNBC cells to chemotherapy, and that using a PTCH1 efflux inhibitor during neoadjuvant or adjuvant therapy could enhance the efficacy of treatment against PTCH1-expressing TNBC, while preventing treatment resistance, relapse, and metastasis formation.

P2, N=30, Active, not recruiting, Sun Yat-sen University

This integrated approach successfully identified H22 as a hemocyanin-derived peptide with moderately potent anticancer activity and promising selectivity. The workflow provides a reproducible proof‑of‑concept framework for computational-guided peptide, warranting further optimization and experimental validation.

These findings confirm that DOX and Zm-093 exhibit synergistic effects on apoptotic pathways in MCF-7 cells, highlighting the potential of Zm-093 as a novel therapeutic agent with improved efficacy and reduced toxicity compared to existing sulfonamide compounds.

P2/3, N=194, Not yet recruiting, Genmab A/S

In this study, we developed an injectable multifunctional hydrogel, MND-ART-GEL, by encapsulating immunostimulatory manganese urate (MnUA), the chemotherapeutic agent doxorubicin (DOX), and an artemisinin derivative, artesunate (ART), within a thermosensitive Pluronic F127 matrix...In orthotopic and postsurgical TNBC mouse models, MND-ART-GEL significantly inhibited tumor growth and recurrence, remodeled the immunosuppressive tumor microenvironment, enhanced CD8+ T-cell infiltration, dendritic cell maturation, and M1 macrophage polarization, reduced PD-1/PD-L1 expression on CD8+ T cells, and promoted the secretion of immune-related cytokines. This study presents a localized drug delivery strategy that integrates chemotherapy, immune modulation, and multitarget synergy, offering a promising approach to overcome therapeutic resistance and reduce recurrence in TNBC.